Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hadassah Medical Organization |
---|---|
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00162474 |
The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin.
The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.
Condition | Intervention |
---|---|
Healthy |
Drug: Warfarin Drug: Phenytoin |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study |
Official Title: | Correlation Between Phenotypic Activity of CYP2C9 and Genetic Polymorphism in CYP2C9 and Warfarin Metabolism. |
Ages Eligible for Study: | 20 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Yoseph Caraco, MD | 00 972 2 6778584 | caraco@hadassah.org.il |
Israel | |
Hadassah Medical Organization | Recruiting |
Jerusalem, Israel | |
Contact: Arik Tzukert, DMD 00 972 2 6776095 arik@hadassah.org.il | |
Contact: Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il | |
Principal Investigator: Yoseph Caraco, MD |
Principal Investigator: | Yoseph Caraco, MD | Hadassah Medical Organization, Jerusalem, Israel |
Study ID Numbers: | yc195510-HMO-CTIL |
Study First Received: | September 11, 2005 |
Last Updated: | October 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00162474 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Healthy Volunteers |
Phenytoin Warfarin Healthy |
Anticoagulants Therapeutic Uses Hematologic Agents Pharmacologic Actions |